<DOC>
	<DOC>NCT02582671</DOC>
	<brief_summary>This study seeks to determine the effectiveness of the interferon-free ABBVIE REGIMEN ± RBV in chronic hepatitis C virus infected participants across Ireland.</brief_summary>
	<brief_title>The Effectiveness of ABT-450/r - Ombitasvir, + Dasabuvir, ± Ribavirin in Patients With Chronic Hepatitis C -An Observational Study in Ireland</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Hepatitis, Chronic</mesh_term>
	<mesh_term>Hepatitis C, Chronic</mesh_term>
	<mesh_term>Ribavirin</mesh_term>
	<criteria>Treatmentnaïve or experienced participants with confirmed CHC, genotype 1, receiving combination therapy with the interferonfree ABBVIE REGIMEN ± RBV according to standard of care and in line with the current local label If RBV is coadministered with the ABBVIE REGIMEN, it has been prescribed in line with the current local label Participants must not be participating or intending to participate in a concurrent interventional therapeutic trial None</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Real World Effectiveness</keyword>
</DOC>